Evidence map›Paper›PMID 30895697›Full record

ArticleEuropean journal of heart failure2019

A trial to evaluate the effect of the sodium-glucose co-transporter 2 inhibitor dapagliflozin on morbidity and mortality in patients with heart failure and reduced left ventricular ejection fraction (DAPA-HF).

John J V McMurray, David L DeMets, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Anna M Langkilde, Felipe A Martinez, Olof Bengtsson, Piotr Ponikowski, Marc S Sabatine and 3 more

Registry-linked trialOpen access · hybridAbstract readClinical Trial Protocol
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of heart failure, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07482943 (The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure), which is not on this map. Cited by 170 papers, 12 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 12 pooled it
41.8field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07482943 phase4recruitingstarted 2026, after this paper: background citation

The Effect of Dapagliflozin on Exercise and Cardiac Functional Status of Patients After Fontan Procedure

Ran2026Enrolled30Registered outcomes13Posted comparisons0ConditionsCardiovascular Diseases, Dapagliflozin, Fontan, Heart FailureArmsDapagliflozin (5-10 mg daily) - SGLT2 Inhibitor Therapy
PMID 37615988PMID 11889012PMID 17543747PMID 19915891PMID 22157969PMID 27257850PMID 29472024PMID 29495980PMID 29663436PMID 30340887PMID 31535829PMID 32098807other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 12 syntheses or guidelines pooled it, 437 citations in OpenAlex.

  1. Pooled it
  2. SGLT2 inhibitors and nephrolithiasis risk: a meta-analysis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2025
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Guideline
  12. Highlights in heart failure.ESC heart failure · 2019
    Pooled it
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 11 institutions in 8 countries.

John J V McMurrayBHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
David L DeMetsDepartment of Biostatistics and Medical Informatics, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Silvio E InzucchiSection of Endocrinology, Yale University School of Medicine, New Haven, CT, USA.
Lars KøberRigshospitalet Copenhagen University Hospital, Copenhagen, Denmark.
Mikhail N KosiborodSaint Luke's Mid America Heart Institute and University of Missouri-Kansas City, Kansas City, MO, USA.
Anna M LangkildeAstraZeneca, Gothenburg, Sweden.
Felipe A MartinezNational University of Cordoba, Cordoba, Argentina.
Olof BengtssonAstraZeneca, Gothenburg, Sweden.
Piotr PonikowskiWroclaw Medical University, Wroclaw, Poland.
Marc S SabatineTIMI Study Group, Division of Cardiovascular Medicine, Brigham and Women's Hospital, and Harvard Medical School, Boston, MA, USA.
Mikaela SjöstrandAstraZeneca, Gothenburg, Sweden.
Scott D SolomonCardiovascular Division, Brigham and Women's Hospital, Boston, MA, USA.
DAPA-HF Committees and Investigators
AstraZeneca (Sweden) · SEAstraZeneca (Netherlands) · NLBrigham and Women's Hospital · USCopenhagen University Hospital · DKHarvard University · USSaint Luke's Hospital · USUniversidad Nacional de Córdoba · ARUniversity of Glasgow · GBUniversity of Wisconsin–Madison · USWroclaw Medical University · PLYale University · US

Funding

AstraZeneca
6 · The paper itself

Abstract

backgroundSodium-glucose co-transporter 2 (SGLT2) inhibitors have been shown to reduce the risk of incident heart failure hospitalization in individuals with type 2 diabetes who have, or are at high risk of, cardiovascular disease. Most patients in these trials did not have heart failure at baseline and the effect of SGLT2 inhibitors on outcomes in individuals with established heart failure (with or without diabetes) is unknown. DESIGN AND

methodsThe Dapagliflozin And Prevention of Adverse-outcomes in Heart Failure trial (DAPA-HF) is an international, multicentre, parallel group, randomized, double-blind, study in patients with chronic heart failure, evaluating the effect of dapagliflozin 10 mg, compared with placebo, given once daily, in addition to standard care, on the primary composite outcome of a worsening heart failure event (hospitalization or equivalent event, i.e. an urgent heart failure visit) or cardiovascular death. Patients with and without diabetes are eligible and must have a left ventricular ejection fraction ≤ 40%, a moderately elevated N-terminal pro B-type natriuretic peptide level, and an estimated glomerular filtration rate ≥ 30 mL/min/1.73 m

conclusionsDAPA-HF will determine the efficacy and safety of the SGLT2 inhibitor dapagliflozin, added to conventional therapy, in a broad spectrum of patients with heart failure and reduced ejection fraction.

Indexed as

Benzhydryl CompoundsCardiovascular DiseasesGlucosidesHeart FailureHospitalizationSodium-Glucose Transporter 2 InhibitorsStroke VolumeChronic DiseaseDiabetes Mellitus, Type 2Double-Blind MethodHumansNatriuretic Peptide, BrainPatient Reported Outcome MeasuresPeptide FragmentsBenzhydryl CompoundsdapagliflozinGlucosidesNatriuretic Peptide, BrainPeptide Fragmentspro-brain natriuretic peptide (1-76)Sodium-Glucose Transporter 2 InhibitorsClinical trialHeart failureSodium-glucose co-transporter 2 inhibitorType 2 diabetes mellitus

Identifiers

PMID30895697
PMCPMC6607736
OpenAlexW2923389432

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.